Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Interventional 9 Expanded_access 1

Sponsor

Cancer Type

Conditions

Desmoid Tumors 1

Interventions

balstilimab 2 zipalertinib 1 tisagenlecleucel 1 telisotuzumab vedotin 1 ribociclib 1 nirogacestat 1 mirdametinib 1 mifamurtide 1 lifileucel 1 leronlimab 1 gallium maltolate 1 futibatinib 1 fluorodopa F 18 1 dodecyl maltoside 1 ceritinib 1 carbon-11 methionine 1 capmatinib 1 brexucabtagene autoleucel 1 Sunitinib 1 Methionine 1 Alpelisib 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × nirogacestat × 90 days × Clear all

NCT05041036 2026-05-08

Individual Patient Compassionate Use of Nirogacestat

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡